Basic Fluorouracil Information

• INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU, Fluorouracilum, Fluorouracilo, Fluouracil).
• Brand Names Available In United Kingdom: not specified.
• ATC Code: L01BC02 (Antineoplastic Agents; Antimetabolites; Pyrimidine Analogues).
• Forms & Dosages: Injection vials commonly 250 mg/5 mL, 500 mg/10 mL and 1 g/20 mL; topical creams and lotions in 0.5%, 1%, 2%, 4% and 5% strengths in 20–40 g tubes or 25 mL bottles.
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: not specified.
• OTC / Rx Classification: Prescription only (Rx).

Latest Research Highlights (UK And EU)

What Have Recent Studies Changed About 5‑FU Safety And Use?

UK and EU reports published between 2022 and 2025 refined the risk–benefit profile of fluorouracil for both systemic oncology and topical dermatology use.

Large multicentre pharmacovigilance analyses across Europe reinforced that DPYD genotyping identifies patients at markedly higher risk of severe myelotoxicity when given systemic 5‑FU.

EU centres increasingly recommend DPYD testing before high‑dose systemic 5‑FU regimens to reduce severe toxicity.

Dermatology trials in the UK compared topical formulations from 0.5% to 5% for actinic keratosis and superficial basal cell carcinoma and showed field clearance rates broadly similar to procedural treatments when used over the recommended 2–6 week courses.

Those dermatology trials also confirmed that topical systemic absorption is generally low and systemic adverse events are rare when creams are used to treat limited fields.

NHS audit data from the period show steady use of capecitabine as an oral alternative for many colorectal protocols while IV 5‑FU remains necessary for specific bolus schedules and combination regimens.

MHRA Yellow Card reports emphasised interaction signals with warfarin and rare neurotoxicity occurring with very high cumulative doses.

Data highlights: DPYD variant prevalence was notable in EU cohorts and is now a routine safety consideration for high‑dose systemic protocols.

Clinical Effectiveness In The United Kingdom

How Well Does Fluorouracil Work In NHS Practice?

Fluorouracil delivers predictable antineoplastic effects when used systemically under oncology protocols and achieves high lesion clearance as a topical agent for actinic keratosis and superficial basal cell carcinoma.

NHS outcome audits indicate outcome parity with capecitabine for certain colorectal regimens when validated protocols and monitoring are followed by oncology multidisciplinary teams.

Primary and secondary care dermatology services commonly choose topical 0.5–5% formulations for field cancerisation where multiple actinic lesions exist.

Patient‑reported outcome measures recorded in NHS dermatology clinics show good cosmetic satisfaction despite temporary erythema, crusting and scaling during active treatment.

Shared decision making is routine when discussing expected local reactions and typical topical durations of 2–6 weeks.

MHRA‑linked reporting and local audits support ongoing monitoring of adverse events and inform local formulary choices.

Indications And Expanded Uses (MHRA And NHS Practice)

When Is Fluorouracil Used In The NHS And Beyond?

MHRA and national formularies list fluorouracil for systemic oncology indications including colorectal, gastric, breast and head and neck cancers within combination regimens.

Topically, it is an established option for actinic keratosis and superficial basal cell carcinoma.

Common off‑label uses in NHS and private dermatology include field treatment for widespread actinic damage, treatment of Bowen’s disease and local management of selected superficial BCCs when surgery is unsuitable.

Dermatology clinics select concentrations between 0.5% and 5% based on site, expected reaction and patient frailty, with typical topical courses lasting 2–6 weeks.

Systemic dosing schedules are protocol‑dependent and defined by oncology MDTs; examples include short bolus courses and continuous infusion schedules within combination regimens.

EU guidance supports DPYD genotyping before high‑dose systemic 5‑FU to reduce the risk of severe toxicity and many NHS trusts have incorporated DPYD flags into e‑prescribing checks.

• MHRA‑Approved Uses: Systemic oncology (multiple tumour types), topical AK and superficial BCC.
• Common Off‑Label Uses: Field treatment for widespread AK, Bowen’s disease, selected superficial BCC when surgery not suitable.

Checklist For Clinicians Considering Topical Versus Systemic Use:

• Confirm lesion type and suitability for topical therapy.
• Assess patient frailty, skin integrity and ability to tolerate local reaction.
• For systemic use, ensure protocol, baseline bloods and DPYD testing where applicable.
• Discuss contraception and pregnancy avoidance for systemic therapy.

Composition And Brand Landscape (United Kingdom Focus)

What Formulations And Brands Are On The Market?

The active ingredient is fluorouracil (INN), commonly referred to as 5‑FU.

The UK market primarily uses generic supply routes from manufacturers such as Teva, Sandoz, Mylan and Pfizer, with EU suppliers like Medac supplying topical preparations across Europe.

International brand names include Adrucil for injection, Efudex / Efudix for topical cream and Actikerall as a topical solution in some EU countries.

Topical strengths available include 0.5%, 1%, 2%, 4% and 5% in 20–40 g tubes, and injection vials commonly come in 250 mg/5 mL, 500 mg/10 mL and 1 g/20 mL sizes.

ATC classification is L01BC02 and WHO lists fluorouracil as an essential medicine.

Hospital formularies and community pharmacies choose between suppliers based on NHS procurement tenders and availability.

Contraindications And Special Precautions

Who Should Not Be Given Fluorouracil?

Absolute contraindications include known hypersensitivity to fluorouracil and pregnancy due to teratogenic risk.

Severe bone marrow suppression or active uncontrolled infection are also absolute contraindications to systemic therapy.

Relative contraindications include significant hepatic or renal impairment, severe cardiac disease and poor nutritional status.

Elderly patients require closer monitoring because organ reserve is often reduced, though universal dose reductions are not always mandated.

DPYD deficiency substantially increases the risk of systemic 5‑FU toxicity and EU guidance recommends genotyping before high‑dose systemic regimens.

Practical daily‑life advice for patients on systemic 5‑FU includes avoiding pregnancy and using contraception during and after treatment, and minimising alcohol while acutely unwell.

Drivers and machine operators should be counselled about possible fatigue and rare neurotoxicity if high cumulative doses are used.

• Checklist For Contraindications: Hypersensitivity, pregnancy, severe marrow suppression, active infection.
• Data Highlight: DPYD testing is recommended in the EU for high‑dose systemic protocols.

Dosage Guidelines (NHS‑Relevant)

What Are Typical Doses For Topical And Systemic Use?

Topical regimens used in NHS practice generally employ 0.5–5% creams applied once or twice daily for 2–6 weeks depending on formulation and treated site.

Systemic IV dosing varies with protocol and tumour type; an example bolus schedule used in some regimens is 12 mg/kg/day (capped) IV bolus for four days followed by alternate dosing as per protocol.

Dose reductions are advised in severe renal or hepatic impairment and paediatric use is specialist only.

Older patients do not automatically require lower starting doses but should be monitored for myelosuppression and mucositis more closely.

Missed topical doses should be applied when remembered unless the next scheduled application is imminent.

Missed IV doses require contacting the oncology team and should not be doubled.

Overdose management is supportive and may require hospitalisation for bone marrow support and treatment of GI or neurotoxic effects.

Interactions Overview (MHRA Yellow Card Context)

Which Medicines And Substances Change 5‑FU Effects?

Fluorouracil potentiates the anticoagulant effect of warfarin and INR monitoring is essential when these are co‑prescribed.

Certain drugs such as allopurinol and some antibiotics including metronidazole have been reported to increase 5‑FU toxicity.

Concomitant cytotoxics add to bone marrow suppression and combined radiotherapy can intensify local skin effects with topical 5‑FU.

Alcohol can worsen mucositis and overall tolerance during systemic therapy and should be minimised while patients are acutely unwell.

MHRA Yellow Card reports have captured rare neurotoxicity and enhanced anticoagulant effects as safety signals, and clinicians are asked to report new adverse events to further UK pharmacovigilance.

Many NHS e‑prescribing systems include DPYD alerts and drug interaction flags to support safe prescribing.

Cultural Perceptions And Patient Habits (United Kingdom)

What Do Patients Say About Topical 5‑FU?

Many UK patients describe topical fluorouracil as a “chemical cream” alternative to cryotherapy, often chosen to avoid scarring from surgery.

Online forums such as Patient.info and popular parenting boards highlight visible local reactions and recovery time as the top patient concerns.

Community pharmacists in major chains are trusted sources of counselling on application technique and side‑effect management for topical therapy.

NHS 111 and GP advice lines remain common first contacts for acute concerns, and long outpatient waits for dermatology can push patients and clinicians to choose field therapy in primary care.

Privacy and cosmetic outcome matter culturally, and many patients prefer a cream even knowing it will cause temporary redness and crusting.

There is growing use of online pharmacies and e‑prescribing, but patients still expect secure NHS linkage and pharmacist validation when ordering medicines online.

• Top Patient Concerns From Forums: Pain on application, appearance during treatment, treatment duration, scarring risk.

Availability And Pricing Patterns (England Versus Scotland, Wales And Northern Ireland)

Where And How Do Patients Get Fluorouracil In The UK?

Fluorouracil is prescription‑only across the UK and is stocked in NHS trusts, hospital pharmacies and major community chains such as Boots and LloydsPharmacy.

England retains NHS prescription charges for many patients while Scotland, Wales and Northern Ireland operate free prescriptions, creating regional differences in out‑of‑pocket cost for topical supplies.

Private dermatology clinics may supply branded topical creams at variable cost and community pharmacies can order generics when requested.

Online pharmacies increasingly dispense topical 5‑FU via NHS electronic prescriptions or private prescription routes, and customers should ensure the product is MHRA‑licensed.

Hospitals typically obtain IV 5‑FU through tendered suppliers such as Teva, Sandoz and Pfizer and local procurement choices determine which generic appears on the formulary.

Note on access: In our online pharmacy, fluorouracil is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Prescribing Preferences

What Are The Alternatives And How Are Choices Made?

Capecitabine is an oral prodrug of 5‑FU often preferred for outpatient colorectal regimens due to convenience and the ability to avoid infusion facilities.

Other systemic alternatives include tegafur combinations and gemcitabine where tumour type and protocol dictate choice.

For dermatology, alternatives to topical 5‑FU include imiquimod, diclofenac gel, photodynamic therapy and cryotherapy, each with different effectiveness and cosmetic trade‑offs.

Imiquimod tends to provoke immune‑mediated inflammation and can be effective in field therapy, diclofenac is milder but typically less effective, and photodynamic therapy gives good cosmesis at the cost of clinic visits.

NHS prescribing preferences balance efficacy, tolerability, patient preference, clinic capacity and cost, and tendering influences which brands are available locally.

Frequently Asked Questions

Q: Will topical 5‑FU cause systemic side effects?

A: Systemic absorption from creams is generally low and most effects are local such as erythema and crusting, but systemic toxicity can occur when large areas or broken skin are treated.

Q: Do I need blood tests for topical treatment?

A: Routine systemic monitoring is not required for limited topical use, but systemic 5‑FU requires regular blood tests for myelosuppression and organ function.

Q: Should I be tested for DPYD variants?

A: EU guidance recommends DPYD genotyping before high‑dose systemic 5‑FU, and many UK centres now offer or mandate testing for such protocols.

Q: Can I buy topical fluorouracil over the counter?

A: No; fluorouracil is prescription‑only in the UK and requires clinical assessment before supply.

Data Highlight: Fluorouracil is a WHO Essential Medicine and remains prescription‑only across jurisdictions.

Guidelines For Proper Use (Pharmacist Counselling And NHS Support)

How Should Pharmacists Counsel Patients Receiving Fluorouracil?

Pharmacists should explain correct application for topical therapy including using gloves or a covered finger, applying a thin layer to the lesion and avoiding healthy surrounding skin.

Counselling should set expectations about local reactions, typical duration of 2–6 weeks and signs that warrant review such as severe pain, spreading redness or signs of infection.

For systemic 5‑FU, pharmacists should review scheduling, antiemetic plans, and the need for blood monitoring and anticoagulant checks if on warfarin.

Pharmacy staff should verify DPYD status is recorded for systemic prescriptions where recommended and flag key interactions in e‑prescribing systems.

Provide written NHS leaflets and signpost patients to NHS 111, local dermatology clinics and MHRA Yellow Card reporting for adverse events.

Online dispensers must ensure identity verification, linkage to GP/NHS records and offer counselling by phone or video before supply.

• Stepwise Counselling Checklist: Confirm indication, discuss application technique, set expectations for reactions, review contraception advice for systemic therapy, confirm monitoring plan.

Definitions For Patients And Staff:

• DPYD: Gene encoding dihydropyrimidine dehydrogenase; variants increase 5‑FU toxicity risk.
• Yellow Card: MHRA adverse‑event reporting system for new safety signals.
• MHRA: Medicines and Healthcare products Regulatory Agency, UK regulator.

Delivery Across United Kingdom